Corpus ID: 29656704

Prolactin as a factor for increased platelet aggregation.

@article{Urban2007ProlactinAA,
  title={Prolactin as a factor for increased platelet aggregation.},
  author={A. Urban and J. Masopust and R. Mal{\'y} and L. Hos{\'a}k and D. Kalnick{\'a}},
  journal={Neuro endocrinology letters},
  year={2007},
  volume={28 4},
  pages={
          518-23
        }
}
Administration of antipsychotics appears to be related to increased risk of venous thromboembolism and cerebrovascular side effects. The biological mechanism responsible for this possible adverse drug reaction is unknown, but there is a growing number of elucidating hypotheses. Treatment with antipsychotics is associated with elevation of prolactin level. Prolactin has recently been recognized as potent platelet aggregation co-activator, and have therefore been postulated as an additional risk… Expand
Risk of venous thromboembolism due to antipsychotic drug therapy
[Venous thromboembolism as an adverse effect of antipsychotic treatment].
Venous Thromboembolism in Recipients of Antipsychotics
Oral administration of 5-hydroxytryptophan aggravated periodontitis-induced alveolar bone loss in rats.
...
1
2
...

References

SHOWING 1-10 OF 43 REFERENCES
Co-activation of platelets by prolactin or leptin--pathophysiological findings and clinical implications.
PRL as a novel potent cofactor for platelet aggregation.
Prolactin receptor signaling during platelet activation.
Hyperprolactinaemia and antipsychotic therapy in schizophrenia
Antipsychotic drugs as a risk factor for venous thromboembolism
Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials
...
1
2
3
4
5
...